My watch list

Eculizumab

Eculizumab^?
Therapeutic monoclonal antibody
Source	Humanized
Target	Complement protein C5
Identifiers
CAS number	219685-50-4
ATC code	L04AA25
PubChem	?
Chemical data
Formula	?
Mol. mass	148 kDa
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	8 to 15 days (mean 11 days)
Excretion	?
Therapeutic considerations
Pregnancy cat.	C(US)
Legal status	℞-only(US)
Routes	Intravenous infusion

Eculizumab (rINN and USAN, trade name Soliris) is a monoclonal antibody directed against the complement protein C5. This antibody blocks the cleavage of C5 and halts the process of complement-mediated cell destruction. Eculizumab is a product of Alexion Pharmaceuticals and has been shown to be effective in treating paroxysmal nocturnal hemoglobinuria.^[1] Eculizumab was approved by the United States Food and Drug Administration (FDA) on March 16, 2007.

Additional recommended knowledge

Correct Test Weight Handling Guide: 12 Practical Tips

Don't let static charges disrupt your weighing accuracy

Recognize and detect the effects of electrostatic charges on your balance

Ecuilzumab exibits it's theraputic activity by bind to the 2b subunit of the C5 convertase enzyme. C5 convertase is produced by the binding of subunits C4b,C2b and C3b on the surface of the bacterium. Binding of Eculizumab to the 2b subunit, results in the reduction of the esterase activity of this subunit, therefore C5 convertase cannot hydrolysize C5 into C5a & C5b subunits respectively.

v • d • e Humanized monoclonal antibodies
Cancer	Alemtuzumab, Apolizumab, Bevacizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Dacetuzumab, Etaracizumab, Etaratuzumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab, Nimotuzumab, Pertuzumab, Sibrotuzumab, Sontuzumab, Tacatuzumab tetraxetan, Trastuzumab
Immunosuppression	Aselizumab, Atlizumab, Cedelizumab, Daclizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Ibalizumab, Lebrilizumab, Mepolizumab, Pascolizumab, Pexelizumab, Reslizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Teplizumab, Tocilizumab, Toralizumab, Visilizumab
Viral infections	Felvizumab, Palivizumab, PRO 140
other	Bapineuzumab, Certolizumab pegol, Eculizumab, Motavizumab, Natalizumab, Ocrelizumab, Omalizumab, Ranibizumab, Tadocizumab, Tefibazumab, Tucotuzumab celmoleukin, Urtoxazumab